Clinical trials: Recurrent Prostate Carcinoma
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Prostate Cancer Recurrent
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive…
- Trial name
- BRaVac (NCT04114825)
- Testing
- RV001V
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- RhoVac APS
Prostate Cancer
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004071
- Testing
- leflunomide, mitoxantrone hydrochloride, prednisone
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Prostate Cancer, Recurrent Prostate Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer
This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer .
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Locally Recurrent Prostate Cancer
- Trial name
- NCT07290998
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Volunteers
- 12 people
- Sponsor
- Alpha Tau Medical LTD.
Recurrent Prostate Cancer
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer.
- Trial name
- NCT01220817
- Testing
- 3 POMx capsules, 1 POMx capsule
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- POM Wonderful LLC
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer
RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.
- Trial name
- NCT00336934
- Testing
- pomegranate juice
- Volunteers
- 183 people
- Sponsor
- Roll International Corporation
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06754085
- Testing
- Florastamin[18F] Injection
- Where
- China
- Volunteers
- 131 people
- Sponsor
- HTA Co., Ltd.
Prostate Cancer
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or…
- Trial name
- NCT07236112
- Testing
- Intravenous (IV) single dose
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- C Ray Therapeutics
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either…
- Trial name
- MEVPRO-1 (NCT06551324)
- Testing
- PF-06821497, Docetaxel, Enzalutamide
- Where
- 224 sites in United States, Argentina and 21 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer (Adenocarcinoma)
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time.
- Trial name
- NCT06655064
- Testing
- None- Observational
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Prostate Cancer
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have…
- Trial name
- NCT00379561
- Testing
- PSA-Activated PSA-PAH1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
High Risk Prostate Carcinoma
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by [18F]Florastamin PET/CT imaging examination to determine the presence of recurrent or…
- Trial name
- NCT05936658
- Testing
- [F-18]Florastamin
- Where
- 6 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- FutureChem